Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. ViewRay rescinds $52m IPO
ViewRay became the latest medical device company to scrap an initial public offering, withdrawing a flotation that would have raised $52 million for its MRI-guided radiation therapy technology.
Oakwood Village, Ohio-based ViewRay had planned to float 4 million shares at $12 to $14 apiece, trading under the “VRAY” symbol on the NASDAQ exchange. Read more
2. More good news for stent thrombectomy
A pair of clinical trials comparing treatment with anti-stroke drugs and stent thrombectomy with drug therapy alone showed reduced disability in stoke patients, bringing more good news for stent thrombectomy device makers.
The studies, sponsored by Medtronic, used the Solitaire stent thrombectomy device it acquired along with Covidien earlier this year. The results were published online today in the New England Journal of Medicine. Read more
1. Renal denervation: Boston Scientific launches new Vessix trial
Boston Scientific said it launched a new clinical trial of its Vessix renal denervation device that’s designed to separate its effects on hypertensive patients from drug therapy.
Marlborough, Mass.-based Boston Scientific said the Reduce-HTN: Reinforce trial will include a 4-week pre-enrollment “washout” period during which patients are weaned from their anti-high blood pressure medications. Read more
